Mylan Resolves Shire Suit Over Generic Fosrenol

By Ben James · June 22, 2011, 6:34 PM EDT

Shire US Inc. on Tuesday ended its patent infringement suit in New York against Mylan Inc. and Matrix Laboratories Ltd. over a generic version of the drug Fosrenol, which reduces phosphate...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Order

Case Information

Case Title

Shire Canada Inc. et al v. Mylan Inc. et al

Case Number

Court

New York Southern

Nature of Suit

Patent

Date Filed

March 19, 2009

Recent Articles By Ben

September 11, 2015
DOL Promises To Hold Off On Enforcing Home Care Rule
June 26, 2015
Gay Marriage Ruling To Boost LGBT Worker Protection Efforts
June 15, 2015
Zero-Tolerance Pot Policies Clear Hurdle In Dish Ruling
June 15, 2015
Dish Worker's Firing For Medical Pot Use Deemed Lawful
May 15, 2015
EEOC Wellness Program Proposal 'Troubling,' Law Prof Says
May 07, 2015
Eye Center's Confidentiality Rule, Firing Ruled Unlawful
May 07, 2015
5 Tips For Employers Worried About Worker Substance Abuse
April 17, 2015
3 Questions About EEOC Rules And Wellness Programs
April 16, 2015
EEOC Issues Proposed Regs On Wellness Programs, ADA
March 20, 2015
EEOC's Proposed Wellness Program Regs Advance To OMB